BioCryst Pharmaceuticals BCRX Operating Lease Liability - Undiscounted Excess Amount
Operating Lease Liability - Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount?
- BioCryst Pharmaceuticals (BCRX) reported operating lease liability - undiscounted excess amount of $5.98M in Q1 2026.
- How has BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount changed year-over-year?
- BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount increased by 9.3% year-over-year, from $5.47M to $5.98M.
- What does operating lease liability - undiscounted excess amount mean?
- This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.